Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.

Qi H, Gao Q, Chen H, Du X, Pan B

PeerJ8 Sept 2026

PMID42729958PMCIDPMC13564392DOI10.7717/peerj.21713PepBankPUB-42729958

Summary

ObjectiveThis study aims to explore the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on weight changes and the occurrence of adverse reactions in overweight or obese adults after drug withdrawal.MethodsComputerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus. The search period was from the establishment of the database to December 2025. Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients. The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.ResultsA total of 699 studies were initially retrieved. Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group. The results of the meta-analysis showed that, compared with the continued treatment group, the weight difference in the discontinuation group was mean difference (MD) = 17.90%, 95% confidence interval (CI) [14.11-21.69], P < 0.0001. It can be seen that there was a significant rebound in weight after drug withdrawal, and there was statistical heterogeneity among the studies (P = 0.0082). Subgroup analysis further revealed that the weight rebound amplitude after discontinuation of tirzepatide was significantly higher than that of semaglutide. This result suggests that the differences in the mechanism of action of different GLP-1RAs may be the reason for the differences in weight changes after discontinuation. In addition, the percentage difference in body weight between after and before drug withdrawal was MD = 9.11%, 95% CI [7.91-10.30], P < 0.0001, further verifying the trend of weight rebound after drug withdrawal. The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.ConclusionThere is a significant weight rebound phenomenon after discontinuation of GLP-1RAs, and the rebound magnitudes vary among different types of drugs. At the same time, there is a risk of adverse reactions during the use of such drugs.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study17

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In overweight/obese adults, weight-rebound magnitude after discontinuing tirzepatide was significantly greater than after discontinuing semaglutide.
In plain wordsIn overweight/obese adults, weight-rebound magnitude was greater after stopping tirzepatide than after stopping semaglutide.
Peptide
Tirzepatide
Outcome
IncreaseWeight rebound amplitude after discontinuation
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis further revealed that the weight rebound amplitude after discontinuation of tirzepatide was significantly higher than that of semaglutide.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
Show in the study text Report a problemFND-4272995804
02HumanSystematic reviewEfficacy outcome
In overweight/obese adults, weight-rebound magnitude after discontinuing semaglutide was significantly smaller than after discontinuing tirzepatide.
In plain wordsIn overweight/obese adults, weight-rebound magnitude was smaller after stopping semaglutide than after stopping tirzepatide.
Peptide
Semaglutide
Outcome
DecreaseWeight rebound amplitude after discontinuation
Study
n: not reported in source
Comparator
Tirzepatide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis further revealed that the weight rebound amplitude after discontinuation of tirzepatide was significantly higher than that of semaglutide.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
Show in the study text Report a problemFND-4272995805

Studies that did not test the peptide alone15

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including liraglutide, discontinuation showed higher weight change than continued treatment (MD 17.90%;95% CI 14.11-21.69;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including liraglutide, stopping treatment showed more weight regain than continuing treatment.
Peptide
Liraglutide
Outcome
IncreaseWeight difference after drug withdrawal
Study
n = 8,993
Comparator
Continued treatment
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
17.9%
withdrawal versus continued treatment;95% CI 14.11-21.69;P < .0001
Source sentences
Summary
The results of the meta-analysis showed that, compared with the continued treatment group, the weight difference in the discontinuation group was mean difference (MD) = 17.90%, 95% confidence interval (CI) [14.11-21.69], P < 0.0001.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4272995801
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including semaglutide, discontinuation showed higher weight change than continued treatment (MD 17.90%;95% CI 14.11-21.69;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including semaglutide, stopping treatment showed more weight regain than continuing treatment.
Peptide
Semaglutide
Outcome
IncreaseWeight difference after drug withdrawal
Study
n = 8,993
Comparator
Continued treatment
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
17.9%
withdrawal versus continued treatment;95% CI 14.11-21.69;P < .0001
Source sentences
Summary
The results of the meta-analysis showed that, compared with the continued treatment group, the weight difference in the discontinuation group was mean difference (MD) = 17.90%, 95% confidence interval (CI) [14.11-21.69], P < 0.0001.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4272995802
05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including tirzepatide, discontinuation showed higher weight change than continued treatment (MD 17.90%;95% CI 14.11-21.69;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including tirzepatide, stopping treatment showed more weight regain than continuing treatment.
Peptide
Tirzepatide
Outcome
IncreaseWeight difference after drug withdrawal
Study
n = 8,993
Comparator
Continued treatment
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
17.9%
withdrawal versus continued treatment;95% CI 14.11-21.69;P < .0001
Source sentences
Summary
The results of the meta-analysis showed that, compared with the continued treatment group, the weight difference in the discontinuation group was mean difference (MD) = 17.90%, 95% confidence interval (CI) [14.11-21.69], P < 0.0001.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4272995803
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including liraglutide, body weight increased after versus before withdrawal (MD 9.11%;95% CI 7.91-10.30;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including liraglutide, body weight was higher after than before withdrawal.
Peptide
Liraglutide
Outcome
IncreaseBody weight difference before and after withdrawal
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
9.11%
after versus before withdrawal;95% CI 7.91-10.30;P < .0001
Source sentences
Summary
In addition, the percentage difference in body weight between after and before drug withdrawal was MD = 9.11%, 95% CI [7.91-10.30], P < 0.0001, further verifying the trend of weight rebound after drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4272995806
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including semaglutide, body weight increased after versus before withdrawal (MD 9.11%;95% CI 7.91-10.30;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including semaglutide, body weight was higher after than before withdrawal.
Peptide
Semaglutide
Outcome
IncreaseBody weight difference before and after withdrawal
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
9.11%
after versus before withdrawal;95% CI 7.91-10.30;P < .0001
Source sentences
Summary
In addition, the percentage difference in body weight between after and before drug withdrawal was MD = 9.11%, 95% CI [7.91-10.30], P < 0.0001, further verifying the trend of weight rebound after drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4272995807
08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In overweight/obese adults across GLP-1 drugs including tirzepatide, body weight increased after versus before withdrawal (MD 9.11%;95% CI 7.91-10.30;P < 0.0001).
In plain wordsIn overweight/obese adults across GLP-1 drugs including tirzepatide, body weight was higher after than before withdrawal.
Peptide
Tirzepatide
Outcome
IncreaseBody weight difference before and after withdrawal
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
9.11%
after versus before withdrawal;95% CI 7.91-10.30;P < .0001
Source sentences
Summary
In addition, the percentage difference in body weight between after and before drug withdrawal was MD = 9.11%, 95% CI [7.91-10.30], P < 0.0001, further verifying the trend of weight rebound after drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4272995808
09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including liraglutide, overall adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including liraglutide, overall side effects decreased after withdrawal.
Peptide
Liraglutide
Outcome
DecreaseOverall adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4272995809
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including semaglutide, overall adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including semaglutide, overall side effects decreased after withdrawal.
Peptide
Semaglutide
Outcome
DecreaseOverall adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4272995810
11HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including tirzepatide, overall adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including tirzepatide, overall side effects decreased after withdrawal.
Peptide
Tirzepatide
Outcome
DecreaseOverall adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4272995811
12HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including liraglutide, gastrointestinal adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including liraglutide, stomach/bowel side effects decreased after withdrawal.
Peptide
Liraglutide
Outcome
DecreaseGastrointestinal adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4272995812
13HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including semaglutide, gastrointestinal adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including semaglutide, stomach/bowel side effects decreased after withdrawal.
Peptide
Semaglutide
Outcome
DecreaseGastrointestinal adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4272995813
14HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including tirzepatide, gastrointestinal adverse reactions decreased after drug withdrawal.
In plain wordsIn overweight/obese adults across GLP-1 drugs including tirzepatide, stomach/bowel side effects decreased after withdrawal.
Peptide
Tirzepatide
Outcome
DecreaseGastrointestinal adverse reactions after withdrawal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4272995814
15HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including liraglutide, cardiovascular-event incidence was reported unaffected by withdrawal; statistical significance was unstated.
In plain wordsIn overweight/obese adults across GLP-1 drugs including liraglutide, cardiovascular-event incidence was reported unchanged after withdrawal.
Peptide
Liraglutide
Outcome
Not applicableCardiovascular events after withdrawal
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4272995815
16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including semaglutide, cardiovascular-event incidence was reported unaffected by withdrawal; statistical significance was unstated.
In plain wordsIn overweight/obese adults across GLP-1 drugs including semaglutide, cardiovascular-event incidence was reported unchanged after withdrawal.
Peptide
Semaglutide
Outcome
Not applicableCardiovascular events after withdrawal
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4272995816
17HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In overweight/obese adults across GLP-1 drugs including tirzepatide, cardiovascular-event incidence was reported unaffected by withdrawal; statistical significance was unstated.
In plain wordsIn overweight/obese adults across GLP-1 drugs including tirzepatide, cardiovascular-event incidence was reported unchanged after withdrawal.
Peptide
Tirzepatide
Outcome
Not applicableCardiovascular events after withdrawal
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.
5 context sentences(design, population, supporting numbers)
Summary · context
Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus.
Summary · context
The search period was from the establishment of the database to December 2025.
Summary · context
Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients.
Summary · context
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.
Summary · context
Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4272995817

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.